Literature DB >> 12357455

MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes.

Chang Chih-Kuang1, Lin Shuan-Pei, Lee Shyue-Jye, Wang Tuen-Jen.   

Abstract

Because of differences in the types and quantities of glycosaminoglycans (GAGs) in various mucopolysaccharidoses (MPSs), MPS screening tests, including the Berry spot and acid turbidity tests, are not specific or sensitive enough for the preliminary diagnosis of MPS. A false-negative result is common. We analyzed urine samples collected from 492 patients who were examined for inborn errors of metabolism using the Berry spot and acid turbidity (qualitative and quantitative) tests. Of those, 48 MPS patients (seven with MPS I, 17 with MPS II, nine with MPS III, 11 with MPS IV, and four with MPS VI) underwent preliminary differentiation between MPS types by two-dimensional electrophoresis (2D-EP), and were confirmed by enzymatic assay. Approximately 21.0% and 7.1% of the 492 samples showed positive reactions in the Berry spot and acid turbidity tests, respectively. Of these, a total of 35 samples with MPS types I, II, and VI showed strong positive reactions in both tests. Five patients with Sanfilippo (MPS III) and six patients with Morquio (IV) syndromes showed false-negative results in both tests. In our study, approximately 13.8% (68 in 492 samples) samples showed a positive reaction in the Berry spot test but a negative one in the acid turbidity test, for unknown reasons. The Berry spot and acid turbidity tests are used extensively for the preliminary diagnosis of MPS in Asia; however, the possibility of a misdiagnosis of MPS type III and IV with both tests should be kept in mind. For accurate diagnosis and confirmation of MPS, the 2D-EP method and enzymatic assay are recommended. They provide high sensitivity, specificity, and efficiency in diagnosing MPS. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12357455      PMCID: PMC6808023          DOI: 10.1002/jcla.10051

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

1.  The spot test is not a reliable screening procedure for mucopolysaccharidoses.

Authors:  J G de Jong; J J Hasselman; A A van Landeghem; H L Vader; R A Wevers
Journal:  Clin Chem       Date:  1991-04       Impact factor: 8.327

2.  Commonly used tests in the detection of Hurler's syndrome.

Authors:  C H Carter; A T Wan; D G Carpenter
Journal:  J Pediatr       Date:  1968-08       Impact factor: 4.406

3.  4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease.

Authors:  J Marsh; A H Fensom
Journal:  Clin Genet       Date:  1985-03       Impact factor: 4.438

4.  Screening tests for glycosaminoglycans in urine: experience from regional interlaboratory surveys.

Authors:  J M Rattenbury; E Worthy; J C Allen
Journal:  J Clin Pathol       Date:  1988-09       Impact factor: 3.411

5.  High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses.

Authors:  J J Hopwood; J R Harrison
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

6.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses.

Authors:  J G de Jong; R A Wevers; C Laarakkers; B J Poorthuis
Journal:  Clin Chem       Date:  1989-07       Impact factor: 8.327

7.  A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA).

Authors:  E A Karpova; J L Keulemans; A T Hoogeveen; B Winchester; I V Tsvetkova; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

8.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).

Authors:  Y V Voznyi; J L Keulemans; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

9.  Prenatal diagnosis of mucopolysaccharidosis by two-dimensional electrophoresis of amniotic fluid glycosaminoglycans.

Authors:  J Mossman; A D Patrick
Journal:  Prenat Diagn       Date:  1982-07       Impact factor: 3.050

10.  Screening test for urinary glycosaminoglycans and differentiation of various mucopolysaccharidoses.

Authors:  K C Huang; K Sukegawa; T Orii
Journal:  Clin Chim Acta       Date:  1985-09-30       Impact factor: 3.786

View more
  22 in total

1.  Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.

Authors:  Min-Ju Chan; Hsuan-Chieh Liao; Michael H Gelb; Chih-Kuang Chuang; Mei-Ying Liu; Hsiao-Jan Chen; Shu-Min Kao; Hsiang-Yu Lin; You-Hsin Huang; Arun Babu Kumar; Naveen Kumar Chennamaneni; Nagendar Pendem; Shuan-Pei Lin; Chuan-Chi Chiang
Journal:  J Pediatr       Date:  2018-11-06       Impact factor: 4.406

2.  Reliability of a visual test for the rapid detection of mucopolysaccharidoses: GAG-test(®).

Authors:  Sergio Lage; José A Prieto; Fernando Andrade; Amaia Sojo; Pablo Sanjurjo; Luis J Aldámiz-Echevarría
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 3.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

4.  Mucopolysaccharidosis type VI in a Miniature Poodle-type dog caused by a deletion in the arylsulphatase B gene.

Authors:  R D Jolly; J J Hopwood; N R Marshall; K S Jenkins; D J Thompson; K E Dittmer; J C Thompson; A O Fedele; K Raj; U Giger
Journal:  N Z Vet J       Date:  2012-02-14       Impact factor: 1.628

Review 5.  Newborn screening and diagnosis of mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Tadashi Fujii; Masaru Fukushi; Toshihiro Oguma; Tsutomu Shimada; Miho Maeda; Kazuhiro Kida; Yuniko Shibata; Hideyuki Futatsumori; Adriana M Montaño; Robert W Mason; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-21       Impact factor: 4.797

Review 6.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

Review 7.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.

Authors:  C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu
Journal:  Mol Genet Metab       Date:  2013-04-10       Impact factor: 4.797

8.  Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.

Authors:  Barbara K Burton; Roberto Giugliani
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

Review 9.  Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.

Authors:  Frits A Wijburg; Grzegorz Węgrzyn; Barbara K Burton; Anna Tylki-Szymańska
Journal:  Acta Paediatr       Date:  2013-02-06       Impact factor: 2.299

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.